Advanced Search

Home > Journals > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Past Issues > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2009 April;53(2) > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2009 April;53(2):157

ISSUES AND ARTICLES   MOST READ   eTOC

CURRENT ISSUETHE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

A Journal on Nuclear Medicine and Molecular Imaging


A Journal on Nuclear Medicine and Molecular Imaging
Affiliated to the Society of Radiopharmaceutical Sciences and to the International Research Group of Immunoscintigraphy
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index (SciSearch), Scopus
Impact Factor 2,413

 

The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2009 April;53(2):157

PET-CT FOR TAILORING THERAPY OF SOLID TUMORS 

Foreword

Larson S. M. 1, Salvatore M. 2

1 Nuclear Medicine ServiceDonna and Benjamin M. Rosen Chair in Radiology Molecular Pharmacology and Chemistry Sloan Kettering Institute Memorial Sloan Kettering Cancer Center, New York, NY, USA
2 PET Section, Nuclear Medicine Service Department of Radiology Memorial Hospital, Memorial Sloan Kettering Cancer Center New York, NY, USA

We take advantage of the special characteristics of human tumors to image tumor response based on the special characteristics of cancers, as a way to image treatment response including predicting susceptibility to specific cancer therapies. The metabolic phenotype of malignancy, includes glycolysis (2-[18F]fluoro-2-D-deoxyglucose [FDG]), increased proliferation (2-[18F]fluoro-L-thymidine [FLT]), increased amino acid transport, as well as other functions such as fatty acid synthesis which have yet to be fully exploited. The endocrine dependent malignancies offer rich opportunities for selective imaging, including radioligand’s that have high affinity for hormone receptors, like AR (16Beta-[18F]16beta-[18F]fluoro-5alpha-dihydrotestosterone [FDHT]) and ER ([18F]fluoroestradiol [FES]) and tissue specific transporters such as sodium iodide symporter (NIS) (124I). As knowledge of cancer biology has grown, it has become possible to develop tracers which image the client proteins involved in response to specific drugs, e.g. Gallium-68-Fab’2 herceptin of HER 2 effected by HSP 90 inhibitor drugs. More and more radiolabeled drugs will be used to explore the pharmacology of anticancer therapies, such as [18F]Desatinib. These may or may not be excellent imaging agents, but as analogs or even true tracers for specific anti-cancer drugs, noninvasive imaging through positron emission tomography will provide highly useful information relating cancer pharmacology within the local tumor to treatment response.

language: English


FULL TEXT  REPRINTS

top of page